Common and rare forms of diabetes mellitus: Towards a continuum of diabetes subtypes

Nature Reviews Endocrinology

Volumn 12, Issue 7, 2016, Pages 394-406

  Flannick, Jason ^a,b   Johansson, Stefan ^c,d   Njølstad, Pål R ^c,d  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; DIABETES MELLITUS; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEREDITY; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; CLASSIFICATION; DNA SEQUENCE; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; RARE DISEASE;

DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; RARE DISEASES; SEQUENCE ANALYSIS, DNA;

EID: 84963575881     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2016.50     Document Type: Review

References (127)

1. World Health Organization. Global status report on noncommunicable diseases. [online], http://www. who. int/ nmh/publications/ncd-status-report-2014/en/ (2014).
2. Anderson, M. S. & Bluestone, J. A. The NOD mouse: A model of immune dysregulation. Annu. Rev. Immunol. 23, 447-485 (2005).
3. Fajans, S. S. & Bell, G. I. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 34, 1878-1884 (2011).
4. Polak, M. & Cave, H. Neonatal diabetes mellitus: A disease linked to multiple mechanisms. Orphanet J. Rare Dis. 2, 12 (2007).
5. Maassen, J. A. et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes 53, S103-S109 (2004).
6. Hattersley, A., Bruining, J., Shield, J., Njolstad, P. & Donaghue, K. C. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr. Diabetes 10 (Suppl. 12), 33-42 (2009).
7. Molven, A. & Njolstad, P. R. Role of molecular genetics in transforming diagnosis of diabetes mellitus. Expert Rev. Mol. Diagn. 11, 313-320 (2011).
8. McCarthy, M. I. & Hattersley, A. T. Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes. Diabetes 57, 2889-2898 (2008).
9. Klupa, T., Skupien, J. & Malecki, M. T. Monogenic models: what have the single gene disorders taught us? Curr. Diab. Rep. 12, 659-666 (2012).
10. Tallapragada, D. S., Bhaskar, S. & Chandak, G. R. New insights from monogenic diabetes for 'common' type 2 diabetes. Front. Genet. 6, 251 (2015).
11. Kahn, S. E., Cooper, M. E. & Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383, 1068-1083 (2014).
12. DeFronzo, R. A., Bonadonna, R. C. & Ferrannini, E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15, 318-368 (1992).
13. Srinivasan, S. & Florez, J. C. Therapeutic challenges in diabetes prevention: we have not found the 'exercise pill'. Clin. Pharmacol. Ther. 98, 162-169 (2015).
14. Shields, B. M. et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53, 2504-2508 (2010).
15. Steele, A. M. et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 311, 279-286 (2014).
16. Isomaa, B. et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 41, 467-473 (1998).
17. Gardner, D. S. & Tai, E. S. Clinical features and treatment of maturity onset diabetes of the young (MODY). Diabetes Metab. Syndr. Obes. 5, 101-108 (2012).
18. Barrett, T. G. & Bundey, S. E. Wolfram (DIDMOAD) syndrome. J. Med. Genet. 34, 838-841 (1997).
19. Semple, R. K., Savage, D. B., Cochran, E. K., Gorden, P. & O'Rahilly, S. Genetic syndromes of severe insulin resistance. Endocr. Rev. 32, 498-514 (2011).
20. Heidet, L. et al. Spectrum of HNF1B mutations in a large cohort of patients who harbor renal diseases. Clin. J. Am. Soc. Nephrol. 5, 1079-1090 (2010).
21. Raeder, H. et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat. Genet. 38, 54-62 (2006).
22. Murphy, R., Ellard, S. & Hattersley, A. T. Clinical implications of a molecular genetic classification of monogenic-cell diabetes. Nat. Clin. Pract. Endocrinol. Metab. 4, 200-213 (2008).
23. Vaxillaire, M. & Froguel, P. Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocr. Rev. 29, 254-264 (2008).
24. Gao, R. et al. Evaluation of a target region capture sequencing platform using monogenic diabetes as a study-model. BMC Genet. 15, 13 (2014).
25. Ellard, S. et al. Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. Diabetologia 56, 1958-1963 (2013).
26. Bonnefond, A. et al. Highly sensitive diagnosis of 43 monogenic forms of diabetes or obesity through one-step PCR-based enrichment in combination with next-generation sequencing. Diabetes Care 37, 460-467 (2014).
27. Alkorta-Aranburu, G. et al. Phenotypic heterogeneity in monogenic diabetes: the clinical and diagnostic utility of a gene panel-based next-generation sequencing approach. Mol. Genet. Metab. 113, 315-320 (2014).
28. Bamshad, M. J. et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12, 745-755 (2011).
29. Bonnefond, A. et al. Molecular diagnosis of neonatal diabetes mellitus using next-generation sequencing of the whole exome. PLoS ONE 5, e13630 (2010).
30. Johansson, S. et al. Exome sequencing and genetic testing for MODY. PLoS ONE 7, e38050 (2012).
31. Lango Allen, H. et al. GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nat. Genet. 44, 20-22 (2012).
32. Bonnefond, A. et al. Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene. PLoS ONE 7, e37423 (2012).
33. Prudente, S. et al. Lossoffunction mutations in APPL1 in familial diabetes mellitus. Am. J. Hum. Genet. 97, 177-185 (2015).
34. Kerns, S. L. et al. A novel variant in CDKN1C is associated with intrauterine growth restriction, short stature, and early-adulthood-onset diabetes. J. Clin. Endocrinol. Metab. 99, E2117-E2122 (2014).
35. AlMaawali, A. et al. Prenatal growth restriction, retinal dystrophy, diabetes insipidus and white matter disease: expanding the spectrum of PRPS1related disorders. Eur. J. Hum. Genet. 23, 310-316 (2015).
36. Thomas, P. M. et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268, 426-429 (1995).
37. Gloyn, A. L. et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6. 2 and permanent neonatal diabetes. N. Engl. J. Med. 350, 1838-1849 (2004).
38. Njolstad, P. R. et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N. Engl. J. Med. 344, 1588-1592 (2001).
39. Lindner, T. H. et al. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor1?. Hum. Mol. Genet. 8, 2001-2008 (1999).
40. Haldorsen, I. S. et al. Lack of pancreatic body and tail in HNF1B mutation carriers. Diabet. Med. 25, 782-787 (2008).
41. Rubio-Cabezas, O. et al. Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities. Diabetes 59, 2326-2331 (2010).
42. Hattersley, A. T. Beyond the beta cell in diabetes. Nat. Genet. 38, 12-13 (2006).
43. Irgens, H. U. et al. Prevalence of monogenic diabetes in the population-based Norwegian Childhood Diabetes Registry. Diabetologia 56, 1512-1519 (2013).
44. Sagen, J. V. et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6. 2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 53, 2713-2718 (2004)
45. Pearson, E. R. et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. N. Engl. J. Med. 355, 467-477 (2006).
46. Pearson, E. R. et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362, 1275-1281 (2003).
47. Chakera, A. J. et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care 38, 1383-1392 (2015).
48. Hemminki, K., Li, X., Sundquist, K. & Sundquist, J. Familial risks for type 2 diabetes in Sweden. Diabetes Care 33, 293-297 (2010).
49. Almgren, P. et al. Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia 54, 2811-2819 (2011).
50. Guan, W., Pluzhnikov, A., Cox, N. J. & Boehnke, M. Meta-analysis of 23 type 2 diabetes linkage studies from the International Type 2 Diabetes Linkage Analysis Consortium. Hum. Hered. 66, 35-49 (2008).
51. Bonnefond, A. & Froguel, P. Rare and common genetic events in type 2 diabetes: what should biologists know? Cell Metab. 21, 357-368 (2015).
52. Mohlke, K. L. & Boehnke, M. Recent advances in understanding the genetic architecture of type 2 diabetes. Hum. Mol. Genet. 24, R85-R92 (2015).
53. Morris, A. P. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44, 981-990 (2012)
54. DIAbetes Genetics Replication Meta-analysis Consortium et al. Genome-wide trans-ancestry metaanalysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat. Genet. 46, 234-244 (2014).
55. Agarwala, V., Flannick, J., Sunyaev, S., GoT2D Consortium & Altshuler, D. Evaluating empirical bounds on complex disease genetic architecture. Nat. Genet. 45, 1418-1427 (2013).
56. Stahl, E. A. et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat. Genet. 44, 483-489 (2012).
57. Maurano, M. T. et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 337, 1190-1195 (2012).
58. Pasquali, L. et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat. Genet. 46, 136-143 (2014).
59. Stitzel, M. L. et al. Global epigenomic analysis of primary human pancreatic islets provides insights into type 2 diabetes susceptibility loci. Cell Metab. 12, 443-455 (2010).
60. The Wellcome Trust Case Control Consortium et al. Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat. Genet. 44, 1294-1301 (2012).
61. Ragvin, A. et al. Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3. Proc. Natl Acad. Sci. USA 107, 775-780 (2010).
62. Claussnitzer, M. et al. FTO obesity variant circuitry and adipocyte browning in humans. N. Engl. J. Med. 373, 895-907 (2015).
63. Smemo, S. et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature 507, 371-375 (2014).
64. Small, K. S. et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat. Genet. 43, 561-564 (2011).
65. Travers, M. E. et al. Insights into the molecular mechanism for type 2 diabetes susceptibility at the KCNQ1 locus from temporal changes in imprinting status in human islets. Diabetes 62, 987-992 (2013).
66. Prokopenko, I. et al. A central role for GRB10 in regulation of islet function in man. PLoS Genet. 10, e1004235 (2014).
67. Claussnitzer, M. et al. Leveraging cross-species transcription factor binding site patterns: from diabetes risk loci to disease mechanisms. Cell 156, 343-358 (2014).
68. Gaulton, K. J. et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat. Genet. 47, 1415-1425 (2015).
69. van de Bunt, M. et al. Transcript expression data from human islets links regulatory signals from genome-wide association studies for type 2 diabetes and glycemic traits to their downstream effectors. PLoS Genet. 11, e1005694 (2015).
70. Hegele, R. A., Cao, H., Harris, S. B., Hanley, A. J. & Zinman, B. The hepatic nuclear factor1 G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. J. Clin. Endocrinol. Metab. 84, 1077-1082 (1999).
71. Altshuler, D. et al. The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26, 76-80 (2000).
72. Gloyn, A. L. et al. Large-scale association studies of variants in genes encoding the pancreatic cell KATP channel subunits Kir6. 2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52, 568-572 (2003).
73. Voight, B. F. et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 42, 579-589 (2010).
74. Fuchsberger, C. et al. Genetic architecture of type 2 diabetes from sequence based analyses. Nature (in the press)
75. Huyghe, J. R. et al. Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion. Nat. Genet. 45, 197-201 (2013).
76. Wessel, J. et al. Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat. Commun. 6, 5897 (2015).
77. Mahajan, A. et al. Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. PLoS Genet. 11, e1004876 (2015).
78. Manning, A. K. et al. A low frequency AKT2 coding variant enriched in the Finnish population is associated with fasting insulin levels. Presented at the 60th Annual Meeting of The American Society of Human Genetics (2014).
79. Voight, B. F. et al. The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet. 8, e1002793 (2012).
80. Moltke, I. et al. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature 512, 190-193 (2014).
81. Steinthorsdottir, V. et al. Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nat. Genet. 46, 294-298 (2014).
82. Lohmueller, K. E. et al. Whole-exome sequencing of 2,000 Danish individuals and the role of rare coding variants in type 2 diabetes. Am. J. Hum. Genet. 93, 1072-1086 (2013).
83. The SIGMA Type 2 Diabetes Consortium et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 311, 2305-2314 (2014).
84. Bonnefond, A. et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat. Genet. 44, 297-301 (2012)
85. Majithia, A. R. et al. Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes. Proc. Natl Acad. Sci. USA 111, 13127-13132 (2014).
86. Laeya, A. et al. Functional investigations of the monogenic diabetes gene HNF1A identify rare variants as risk factors for type 2 diabetes in the general population. Diabetes 64 (Suppl 1) A460 (2015).
87. Flannick, J. et al. Lossoffunction mutations in SLC30A8 protect against type 2 diabetes. Nat. Genet. 46, 357-363 (2014).
88. Flannick, J. et al. Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat. Genet. 45, 1380-1385 (2013).
89. Guey, L. T. et al. Power in the phenotypic extremes: A simulation study of power in discovery and replication of rare variants. Genet. Epidemiol. 35, 236-246 (2011).
90. Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117-1130 (2003).
91. Terwilliger, J. D. & Weiss, K. M. Confounding, ascertainment bias, and the blind quest for a genetic 'fountain of youth'. Ann. Med. 35, 532-544 (2003).
92. Goring, H. H., Terwilliger, J. D. & Blangero, J. Large upward bias in estimation of locus-specific effects from genomewide scans. Am. J. Hum. Genet. 69, 1357-1369 (2001).
93. Gail, M. & Chatterjee, N. in Proceedings of the Second Seattle Symposium in Biostatistics (Seattle, 2004).
94. MacArthur, D. G. et al. A systematic survey of lossoffunction variants in human protein-coding genes. Science 335, 823-828 (2012).
95. Kohane, I. S., Hsing, M. & Kong, S. W. Taxonomizing, sizing, and overcoming the incidentalome. Genet. Med. 14, 399-404 (2012).
96. Sulem, P. et al. Identification of a large set of rare complete human knockouts. Nat. Genet. 47, 448-452 (2015).
97. Plon, S. E. et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 29, 1282-1291 (2008).
98. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405-424 (2015).
99. Boj, S. F., Parrizas, M., Maestro, M. A & Ferrer, J. A transcription factor regulatory circuit in differentiated pancreatic cells. Proc. Natl Acad. Sci. USA 98, 14481-14486 (2001).
100. Odom, D. T. et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 303, 1378-1381 (2004).
101. Baumhueter, S. et al. HNF1 shares three sequence motifs with the POU domain proteins and is identical to LFB1 and APF. Genes Dev. 4, 372-379 (1990).
102. Teslovich, T. M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713 (2010).
103. Erdmann, J. et al. New susceptibility locus for coronary artery disease on chromosome 3q22. 3. Nat. Genet. 41, 280-282 (2009).
104. Groop, L. & Pociot, F. Genetics of diabetes-are we missing the genes or the disease? Mol. Cell. Endocrinol. 382, 726-739 (2014).
105. Melnikov, A. et al. Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. Nat. Biotechnol. 30, 271-277 (2012).
106. Melnikov, A., Rogov, P., Wang, L., Gnirke, A. & Mikkelsen, T. S. Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes. Nucleic Acids Res. 42, e112 (2014).
107. Cooper, G. M. Parlez-vous VUS? Genome Res. 25, 1423-1426 (2015).
108. MacArthur, D. G. et al. Guidelines for investigating causality of sequence variants in human disease. Nature 508, 469-476 (2014).
109. George, S. et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304, 1325-1328 (2004).
110. Tan, K. et al. Analysis of genetic variation in Akt2/ PKB-in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes. Diabetes 56, 714-719 (2007).
111. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014).
112. Pearson, E. R., Liddell, W. G., Shepherd, M., Corrall, R. J. & Hattersley, A. T. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor1 gene mutations: evidence for pharmacogenetics in diabetes. Diabet. Med. 17, 543-545 (2000).
113. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747-753 (2009)
114. McClellan, J. & King, M. C. Genetic heterogeneity in human disease. Cell 141, 210-217 (2010).
115. Cirulli, E. T. & Goldstein, D. B. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat. Rev. Genet. 11, 415-425 (2010).
116. The International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752 (2009).
117. Yang, J. et al. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42, 565-569 (2010).
118. Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
119. Jostins, L. & Barrett, J. C. Genetic risk prediction in complex disease. Hum. Mol. Genet. 20, R182-R188 (2011).
120. Musunuru, K. et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466, 714-719 (2010).
121. Risch, N. J. Searching for genetic determinants in the new millennium. Nature 405, 847-856 (2000).
122. Altshuler, D., Daly, M. J. & Lander, E. S. Genetic mapping in human disease. Science 322, 881-888 (2008). Reference 123 is a thorough review of the history of genetic mapping.
123. Reich, D. E. & Lander, E. S. On the allelic spectrum of human disease. Trends Genet. 17, 502-510 (2001). Reference 124 is responsible for much of the motivation behind GWAS.
124. Bamshad, M. J. et al. The Centers for Mendelian Genomics: A new large-scale initiative to identify the genes underlying rare Mendelian conditions. Am. J. Med. Genet. A 158A, 1523-1525 (2012).
125. Beaulieu, C. L. et al. FORGE Canada Consortium: outcomes of a 2year national rare-disease gene-discovery project. Am. J. Hum. Genet. 94, 809-817 (2014).
126. Wright, C. F. et al. Genetic diagnosis of developmental disorders in the DDD study: A scalable analysis of genome-wide research data. Lancet 385, 1305-1314 (2015).
127. Yang, Y. et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N. Engl. J. Med. 369, 1502-1511 (2013).